vs
AdvanSix Inc.（ASIX）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Bio-Techne的1.2倍（$359.9M vs $311.4M），Bio-Techne净利率更高（16.4% vs -0.8%，领先17.2%），AdvanSix Inc.同比增速更快（9.4% vs -1.5%），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs 1.3%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
ASIX vs TECH — 直观对比
营收规模更大
ASIX
是对方的1.2倍
$311.4M
营收增速更快
ASIX
高出10.9%
-1.5%
净利率更高
TECH
高出17.2%
-0.8%
两年增速更快
ASIX
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $311.4M |
| 净利润 | $-2.8M | $51.0M |
| 毛利率 | 7.6% | 66.9% |
| 营业利润率 | -0.7% | 24.2% |
| 净利率 | -0.8% | 16.4% |
| 营收同比 | 9.4% | -1.5% |
| 净利润同比 | -892.9% | 126.0% |
| 每股收益（稀释后） | $-0.11 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXTECH
| Q1 26 | — | $311.4M | ||
| Q4 25 | $359.9M | $295.9M | ||
| Q3 25 | $374.5M | — | ||
| Q2 25 | $410.0M | $317.0M | ||
| Q1 25 | $377.8M | $316.2M | ||
| Q4 24 | $329.1M | $297.0M | ||
| Q3 24 | $398.2M | $289.5M | ||
| Q2 24 | $453.5M | $306.1M |
净利润ASIXTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-2.8M | $38.0M | ||
| Q3 25 | $-2.6M | — | ||
| Q2 25 | $31.4M | $-17.7M | ||
| Q1 25 | $23.3M | $22.6M | ||
| Q4 24 | $352.0K | $34.9M | ||
| Q3 24 | $22.3M | $33.6M | ||
| Q2 24 | $38.9M | $40.6M |
毛利率ASIXTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | 7.6% | 64.6% | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | 62.7% | ||
| Q1 25 | 14.2% | 67.9% | ||
| Q4 24 | 3.4% | 65.3% | ||
| Q3 24 | 14.4% | 63.2% | ||
| Q2 24 | 17.9% | 66.4% |
营业利润率ASIXTECH
| Q1 26 | — | 24.2% | ||
| Q4 25 | -0.7% | 18.4% | ||
| Q3 25 | -0.9% | — | ||
| Q2 25 | 7.7% | -7.5% | ||
| Q1 25 | 7.7% | 12.2% | ||
| Q4 24 | -3.9% | 16.0% | ||
| Q3 24 | 7.5% | 13.8% | ||
| Q2 24 | 11.5% | 15.0% |
净利率ASIXTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | -0.8% | 12.8% | ||
| Q3 25 | -0.7% | — | ||
| Q2 25 | 7.7% | -5.6% | ||
| Q1 25 | 6.2% | 7.1% | ||
| Q4 24 | 0.1% | 11.7% | ||
| Q3 24 | 5.6% | 11.6% | ||
| Q2 24 | 8.6% | 13.3% |
每股收益（稀释后）ASIXTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.11 | $0.24 | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.15 | $-0.11 | ||
| Q1 25 | $0.86 | $0.14 | ||
| Q4 24 | $0.02 | $0.22 | ||
| Q3 24 | $0.82 | $0.21 | ||
| Q2 24 | $1.43 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $2.1B |
| 总资产 | $1.7B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | $19.8M | $172.9M | ||
| Q3 25 | $23.7M | — | ||
| Q2 25 | $18.4M | $162.2M | ||
| Q1 25 | $8.3M | $140.7M | ||
| Q4 24 | $19.6M | $177.5M | ||
| Q3 24 | $17.3M | $187.5M | ||
| Q2 24 | $12.1M | $152.9M |
总债务ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
股东权益ASIXTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $815.2M | $2.0B | ||
| Q3 25 | $818.2M | — | ||
| Q2 25 | $823.7M | $1.9B | ||
| Q1 25 | $794.4M | $2.0B | ||
| Q4 24 | $774.6M | $2.1B | ||
| Q3 24 | $766.4M | $2.1B | ||
| Q2 24 | $746.6M | $2.1B |
总资产ASIXTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.6B | $2.6B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.5B | $2.7B | ||
| Q2 24 | $1.5B | $2.7B |
负债/权益比ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | — |
| 自由现金流经营现金流 - 资本支出 | $36.1M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 7.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | — |
8季度趋势，按日历期对齐
经营现金流ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | — | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $21.1M | $98.2M | ||
| Q1 25 | $11.4M | $41.1M | ||
| Q4 24 | $64.2M | $84.3M | ||
| Q3 24 | $57.3M | $63.9M | ||
| Q2 24 | $50.2M | $75.5M |
自由现金流ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | $93.3M | ||
| Q1 25 | $-22.6M | $31.0M | ||
| Q4 24 | $29.8M | $77.5M | ||
| Q3 24 | $26.8M | $54.7M | ||
| Q2 24 | $16.7M | $57.5M |
自由现金流率ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | 29.4% | ||
| Q1 25 | -6.0% | 9.8% | ||
| Q4 24 | 9.1% | 26.1% | ||
| Q3 24 | 6.7% | 18.9% | ||
| Q2 24 | 3.7% | 18.8% |
资本支出强度ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | 1.5% | ||
| Q1 25 | 9.0% | 3.2% | ||
| Q4 24 | 10.4% | 2.3% | ||
| Q3 24 | 7.7% | 3.2% | ||
| Q2 24 | 7.4% | 5.9% |
现金转化率ASIXTECH
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | 1.82× | ||
| Q4 24 | 182.29× | 2.42× | ||
| Q3 24 | 2.57× | 1.90× | ||
| Q2 24 | 1.29× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
